{
  "id": 7042141,
  "title": "Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer",
  "url": "https://urgent.news/2026/09/13/tam-peli-extends-survival-by-nearly-four-months-in-relapsed-small",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-13T01:50:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-tam-peli-survival-months-relapsed.html"
  },
  "original_language": "en",
  "account": "The TAISHAN-302 trial revealed that tambotatug pelitecan (Tam-Peli) significantly improved overall survival, progression-free survival and objective response rate compared to topotecan in patients with relapsed small-cell lung cancer (SCLC). The randomized, open-label study enrolled 451 patients, with 225 receiving Tam-Peli and 226 receiving topotecan. Tam-Peli reduced the risk of death by 54% and increased median overall survival by 4 months (13.3 months vs 9.4 months). It also improved progression-free survival by 71% (7.4 months vs 2.8 months) and response rate by 49.4% (59.1% vs 9.7%). The safety profile was manageable, with no new safety signals identified and no treatment-related deaths in the Tam-Peli group. These results suggest Tam-Peli as a potential new standard-of-care option for second-line SCLC treatment.",
  "summary": "The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC)…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "MedPage Today",
        "title": "Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer",
        "url": "https://urgent.news/2026/09/13/significant-survival-boost-with-novel-adcs-in-relapsed-small-cell",
        "published": "2026-09-13T20:45:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}